Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.88% | -321.27% | -125.34% | 243.33% | -1.22% |
| Total Depreciation and Amortization | -13.02% | 0.60% | 2.77% | -3.11% | -1.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -101.07% | 97.91% | 136.12% | -26.03% | 60.77% |
| Change in Net Operating Assets | -183.57% | 156.11% | -66.45% | -364.08% | -63.37% |
| Cash from Operations | -94.69% | 37.18% | -214.88% | 248.35% | -117.70% |
| Capital Expenditure | -449.32% | -53.15% | 66.11% | -313.73% | 87.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 405.09% | 112.73% | -20,421.81% | -25.39% | -100.37% |
| Cash from Investing | 403.91% | 112.37% | -8,785.33% | -107.54% | -100.52% |
| Total Debt Issued | -- | -100.00% | 2.04% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13,000.00% | 0.00% | -91.67% | -99.96% | 39,406.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,532,100.00% | -100.00% | 1.99% | -16.16% | 39,406.76% |
| Foreign Exchange rate Adjustments | 408.89% | -184.11% | 1,170.00% | 95.19% | -218.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.49% | 72.48% | -233.88% | 2,139.21% | -106.47% |